Tuesday, July 31, 2018

APLS To Report Data In 2H, CUR Abuzz, Shire Discontinues NASH Trial

Today's Daily Dose brings you news about Apellis Pharma's pipeline progress; licensing agreement between Knight Therapeutics and TherapeuticsMD; anticipated milestones of Progenics Pharma, and discontinuation of Shire's phase II NASH trial.

from RTT - Biotech https://ift.tt/2OAbj0y
via IFTTT

No comments:

Post a Comment